Figures
Abstract
Plasmodium falciparum resistance to artemisinin has emerged in the Greater Mekong Subregion and now poses a threat to malaria control and prevention. Recent work has identified mutations in the kelch propeller domain of the P. falciparum K13 gene to be associated artemisinin resistance as defined by delayed parasite clearance and ex vivo ring stage survival assays. Species specific primers for the two most prevalent human malaria species, P. falciparum and P. vivax, were designed and tested on multiple parasite isolates including human, rodent, and non- humans primate Plasmodium species. The new protocol described here using the species specific primers only amplified their respective species, P. falciparum and P. vivax, and did not cross react with any of the other human malaria Plasmodium species. We provide an improved species specific PCR and sequencing protocol that could be effectively used in areas where both P. falciparum and P. vivax are circulating. To design this improved protocol, the kelch gene was analyzed and compared among different species of Plasmodium. The kelch propeller domain was found to be highly conserved across the mammalian Plasmodium species.
Citation: Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, et al. (2015) Genetic Analysis and Species Specific Amplification of the Artemisinin Resistance-Associated Kelch Propeller Domain in P. falciparum and P. vivax. PLoS ONE 10(8): e0136099. https://doi.org/10.1371/journal.pone.0136099
Editor: Luzia Helena Carvalho, Centro de Pesquisa Rene Rachou/Fundação Oswaldo Cruz (Fiocruz-Minas), BRAZIL
Received: May 4, 2015; Accepted: July 29, 2015; Published: August 20, 2015
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The authors acknowledge funding support from the CDC Advanced Molecular Detection Initiative. ET is supported by the Atlanta Research and Education Foundation and SMC by the American Society of Microbiology postdoctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that they have no competing interests.
Introduction
Following the development and spread of resistance to antimalarials such as chloroquine and sulfadoxine-pyrimethamine, artemisinin-based combination therapy (ACT) was adopted as first-line treatment for uncomplicated Plasmodium falciparum malaria worldwide [1]. However, resistance to artemisinin, as measured by delayed parasite clearance, has now been confirmed in multiple countries in the Greater Mekong Subregion [2–10]. There is growing concern that artemisinin resistance may spread from this region to Africa and other parts of Asia as was the case with chloroquine and sulfadoxine-pyrimethamine resistance [11–13].
While in vivo therapeutic efficacy studies (TES) are considered the gold standard for determining anti-malarial efficacy, the WHO recommends that data from these studies be complemented with molecular markers of drug resistance [1]. After a long search to identify a specific locus implicated in artemisinin resistance, the kelch propeller domain of the K13 gene (PF3D7_1343700) on chromosome 13 was recently identified as a molecular marker of artemisinin resistance [14]. Several mutations in the kelch propeller domain have now been associated with in vitro ring stage survival assays and delayed parasite clearance rates in patients treated with artemisinins [8, 14]. As a result, sequencing the kelch propeller domain of the K13 gene is becoming an important tool in the global surveillance of antimalarial drug resistance in P. falciparum [8–10, 14–19].
While P. falciparum is the dominant species that causes human malaria worldwide and contributes the most to mortality, P. vivax is more prevalent than P. falciparum in many regions of the Greater Mekong Subregion [20]. Interestingly, a recent study showed that non-synonymous mutations in the P.vivax ortholog K12 gene are already circulating at very low frequencies in Cambodia [21]. While chloroquine remains the primary treatment option for P. vivax infections, ACTs have also been found to be efficacious in clinical trials in Asia and may be used as an alternative treatment to chloroquine [22, 23]. In addition, widespread use of ACTs for P. falciparum infection may exert some indirect selective pressure on the P. vivax kelch gene in individuals with mixed P. falciparum and P. vivax infections. Moreover, in areas where mefloquine has been extensively used as the first-line treatment in falciparum-uncomplicated malaria, high frequencies of P. falciparum and P. vivax isolates with increased mdr-1 copy numbers [24] have been observed. These findings suggest that antimalarial drugs used to treat falciparum malaria may have a significant impact on sympatric Plasmodium species [21].
In areas where both P. falciparum and P. vivax coexist, kelch gene amplification must be species specific; otherwise, non-specific amplification using P. falciparum and P. vivax clinical isolates, might lead to incorrect classification of polymorphisms. Although microscopy remains standard practice for malaria diagnosis, molecular methods such as PCR based protocols for the confirmation of Plasmodium species can also be used [25]. Here, we provided a P. falciparum and a P.vivax species-specific protocol for accurately amplifying and sequencing the kelch propeller domain of these two species.
Materials and Methods
Parasite isolates
The following species and strains of parasites archived at the Malaria Laboratory, Research and Development Unit, Center for Disease Control and Prevention (CDC) were analyzed: P. falciparum (strains: W2, 7G8, FCR3, Dd2, 3D7, HB3, Honduras I/CDC, Panama II, Brazil, Malayan IV, and Santa Lucia), P. vivax (strains: India VII, Nicaragua I, Belem, Mauritania II, Ecuador I, Eritrea I, Indonesia XIX, and Vietnam II), P. malariae (Uganda I), P. ovale (Nigeria I), P. reichenowi, P. cynomolgi (strains: PTI, Berok, Cambodia, Smithsonian, Gombok), P. fieldi (AB introlatus), P. simiovale, P. simium, P. knowlesi (strains: Philippines, Malayan), P. gonderi, P. hylobati, P. inui (Taiwan, Philippines), P. berghei, and P. yoeli. DNA was isolated using the commercially available QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA). Genomic DNA was eluted with 100 μl of elution buffer and stored at −20°C for use in PCR assays. All isolates were screened using PET-PCR [26, 27] and confirmed to be positive for Plasmodium.
Species specific primer design and genetic analysis
Primers specific for the kelch K13 gene (PF3D7_1343700) for Plasmodium falciparum and the ortholog kelch K12 gene in Plasmodium vivax were designed using the Geneious Pro R8 software (www.geneious.com). Briefly, Geneious Pro R8 was used to perform a BLAST search using the reference P. falciparum K13 gene sequence (PF3D7_134700) and download matching and published kelch gene Plasmodium sequences (Accession number: NC_009917, P.vivax; NC_020405, P. cynomolgi strain B; NW_008481840P. inui; NC_011913, P. knowlesi; NW_672329, P. berghei; NC_020405, NW_875089; P.chabaudi; and NW_865350, P. yoelii; CDO66221, protein, P. reichenowi). Sequences were aligned and analyzed for regions of sequence identity. Using the principle of allelic exclusion, different sets of species specific primers were designed and mapped onto the aligned sequences, aiming for primers that differentiate species by destabilizing the 3’ end via mismatched nucleotides. We tested P. falciparum and P. viax species specific primers on various P. falciparum and P. vivax strains derived from various geographical origins as well as on other human, non-human primate, and rodent malaria species. Lastly, our protocol was compared to an original published protocol for the amplification of the K13 gene in P. falciparum [14].
PCR amplification and sequencing of the Plasmodium kelch propellor domain
The kelch gene from different Plasmodium species was amplified using a nested PCR approach. The species specific primers used for amplification of the kelch propeller domain are shown in Table 1. Two μL of genomic DNA was amplified using 0.5 μM of each primer, 0.2mM dNTP, 2 mM MgCl2 for the primary and secondary reactions, and 1 U Expand High Fidelity Taq (Roche CA, USA). For the primary reaction the following cycling parameters were used: 5 min at 94°C, 35 cycles at 94°C for 30 sec, 46°C for 60 sec (for P. falciparum primers) or 61°C for 60 sec (for P. vivax primers), 72°C for 90 sec, and final extension for 5 min at 72°C. For the nested PCR, 1μL of 1/5 diluted primary PCR product was used as template. For the nested PCR reaction the following cycling parameters were used: 2 min at 94°C, 35 cycles at 94°C for 30 sec, 55°C for 30 sec (P. falciparum primers) or 59°C for 30 sec (P. vivax primers), 72°C for 90 sec, and final extension for 5 min at 72°C. PCR products were confirmed using a 2% agarose gel electrophoresis and Gel red (Biotium, Hayward, CA USA). For cycle sequencing, 2.0uL Big Dye and Dye Buffer, 0.32 uL Primer (stock primer concentration of 10uM), 1.0uL of 1/5 diluted secondary PCR product, and 5.32uL of sterile water were used per reaction with the following cycling parameters: 96.0°C for 60 sec, 30 cycles 96.0°C for 10s, 50.0°C for 5 sec, and 70.0°C for 4 min. The original K13 amplification protocol [14] was used for comparison with the protocol described in this study. Sanger sequencing of PCR products was performed using ABI 3130 (Applied Biosystems, CA, USA). The sequence data was analyzed using Geneious Pro R8 software (www.geneious.com).
Primary and secondary PCR primers for each species and respective annealing temperatures are shown.
Plasmodium kelch propeller sequences submitted to Genbank
All of the geographically distinct P. falciparum and P. vivax isolates sequenced for the propeller domain were identical on both the nucleotide and amino acid level to the P. falciparum 3D7 (PF3D7_134700) isolate and P. vivax Sal-1 (NC_009917) isolate already available in Genbank, respectively. The following non-human primate isolates were also successfully amplified and sequenced: P. cynomolgi (Gombok), P. simium, P. simiovale and P. inui. Any new sequences reported in this study were deposited in Genbank under the accession numbers: KT198970-KT198972.
3D structural modeling of the loop region
The protein structure of the Keap1 protein (Protein Data Bank: 2Z32) was used to generate the P. falciparum K13 propellor domain using the USCSF Chimera plugin MODELLER [28].
Results
Comparison of the kelch propeller domain in human, non-human primates, and rodent Plasmodium species
The P. falciparum (PF3D7_1343700) K13 gene is 2,181 nucleotide base pairs, encoding a protein of 727 amino acids (Fig 1), whereas the P. vivax (Sal-1 NC_009917) ortholog K12 gene is 2,139 base pairs, corresponding to 713 amino acids. The difference in length is due to nucleotide deletions found at the 5’ end of the P. vivax sequence at positions: 12, 407, 446, 472, and 534 with respect to the P. falciparum sequence (Fig 2). Comparison of the entire coding region of the kelch gene between P. falciparum and P. vivax revealed the gene to be 80% identical at the nucleotide level and 88% identical at the amino acid level. However, when the comparison was restricted to the kelch propeller domain only, the two genes were 80% identical at the nucleotide level and 97% at the amino acid level (Table 2).
(A) Schematic depicting the P. falciparum K13 gene size and propeller domain region. A 3D model is shown for the predicted propeller domain. (B) Species specific nested PCR workflow for amplifying the K13 gene and propeller domain. The protein structure of the Keap1 protein (Protein Data Bank: 2Z32) was used to generate the 3D model of the P. falciparum K13 propellor domain.
Nucleotide and amino acid sequence alignment of the kelch gene for P. falciparum and P. vivax; disagreements in nucleotide (black) and amino acid (color) are highlighted. The yellow annotation above the sequence indicates the gene region that encodes the kelch propeller domain; blue squares over the P. falciparum sequence denotes K13 propeller mutations reported by Ariey et al [14]. Forward primers are annotated in dark green and reverse primers in light green. Shown are sequences for the isolates 3D7 (P. falciparum) and Sal-1 (P. vivax).
Amino acid and nucleotide sequence percent (%) identify (e.g. percent of residues that are identical) are shown in the table. Amino acid similarity is shown in bold numbers and nucleotide similarity in italicized numbers.
All of the geographically distinct P. falciparum and the P. vivax isolates sequenced for the kelch propeller domain were identical on both the nucleotide and amino acid level to the P. falciparum 3D7 (PF3D7_134700) isolate and P. vivax Sal-1 isolate (NC_009917), respectively. A total of eight amino acid differences within the kelch propeller domain (spanning 301 amino acids in length) between all of the P. falciparum and of P. vivax strains were found at the following positions: 448, 517, 519, 568, 578, 605, 691, and 708 (Table 3). The kelch propeller domain is relatively conserved among the rodent and primate species of Plasmodium (Table 2, S1 and S2 Figs). Nucleotide and amino acid comparison for the various Plasmodium species is presented in Table 2.
Relative to alignment between P. falciparum 3D7 and P. vivax Sal-I.
Kelch propeller domain species specific amplification
The final P. falciparum nested PCR product size using species specific primers was 784 bp for P. falciparum and 792 bp for P. vivax. The P. falciparum primers designed in this study amplified all P. falciparum strains tested, but not any other Plasmodium species (Fig 3). In contrast, the previously published protocol showed non-specific amplification with other Plasmodium species, S3 Fig.
The Plasmodium falciparum species specific primers were tested on multiple Plasmodium species, including human, rodent, and non-human primate malaria parasites from various geographical regions. The expected K13 propeller domain PCR product for P. falciparum is 784 base pairs. Panels (A) and (B) show human malaria parasites tested; Panel (C) shows non-human primate and rodent malaria parasites tested. Blue text denotes samples that were amplified by the PCR protocol.
The P.vivax primers amplified eight different P. vivax strains derived from various geographical regions as well as five closely related non-human primate malaria parasites: P. cynomolgi-Gombok strain, P. simium, P. simiovale, P. inui, and P. hylobati (Fig 4). However, only P. cynomolgi-Gombok strain, P. simium, P. simiovale, and P. inui could be sequenced. Interestingly, of the five P. cynomolgi strains tested, only the Gombok strain showed cross reactivity with the P. vivax primers (Fig 4). Neither the P. falciparum nor P. vivax primers amplified the other human malaria parasites P. malariae, P. ovale and P. knowlesi, or the rodent malaria parasites P. bergehi and P. yoelii (Figs 3 and 4).
The Plasmodium vivax species specific primers were tested on multiple Plasmodium species, including human, rodent, and non-human primate malaria parasites from various geographical regions. The expected K12 propeller domain PCR product for P. vivax is 792 base pairs. Panels (A) and (B) show human malaria parasites tested; Panel (C) shows non-human primate and rodent malaria parasites tested. Blue text denotes samples that were amplified by the PCR protocol.
Discussion
In some endemic regions often P. vivax is more prevalent than P. falciparum [29, 30], and co-infections can be common. Artemisinin combination therapy has been in use since the early 2000s in numerous malaria endemic regions where P. falciparum and P. vivax co-exist [1]. While drug resistance in P. falciparum has primarily been the recent focus of research, the study of resistance in P. vivax has received limited attention. For example, to date only one other paper investigating kelch propeller domain mutations in P. vivax has been published [21]. In this study, we successfully designed a species specific protocol for the detection of K13 propeller domain mutations associated with artemisinin drug resistance in P.falciparum
The previously published protocol [14] was found to show non-specific amplification with multiple Plasmodium species (S3 Fig), including the two major human malaria species P. falciparum and P. vivax. While we were unable to successfully sequence the full length P. vivax kelch propeller domain using the previous protocol, we did obtain truncated sequence data for P. vivax using the published P. falciparum primers [14]. This can cause some uncertainty in the interpretation of sequence data.
The P. falciparum primers in our study were able to amplify different strains of P. falciparum indicating that this protocol will be useful for amplify and sequence the kelch propeller domain from several P.falciparum isolates from various regions around the world (Brazil, Honduras, Panama, and Malaysia). Importantly, the P. falciparum primers did not show amplification of any other human Plasmodium parasites (Fig 3).
Similarly, the P. vivax primers did not cross react with P. falciparum or any other human malaria parasites. Further, the P. vivax primers amplified successfully P. vivax strains collected from different geographical origins (Fig 3). The P. vivax primers showed evidence of some cross-reaction with P. cynomolgi-Gombok strain, P. simium, P. simiovale, and P. inui (Fig 4). This was expected, since most of these species are evolutionarily and genetically related to P. vivax [31]. Out of the five P. cynomolgi lab isolates tested only the Gombok strain cross-reacted with the P. vivax primers, which could be attributed to the known diversity within the two major sub-groups of P. cynomolgi [31]. Although this primer set was cross reactive with some of the non-human primate malaria parasites, this may not be a limitation for the amplification of field samples since most of these non-human primate parasites are not commonly transmitted naturally to humans. The only currently known zoonotic malaria is caused by P. knowlesi, which showed no cross reaction with either the P. falciparum or P. vivax species specific protocol.
Given that currently the K13 gene can serve as a effective molecular marker of artemisinin resistance, we emphasize the importance of using our species specific protocol for routine screening of K13 artemisinin associated resistant alleles.
Supporting Information
S1 Fig. Nucleotide sequence alignment of the kelch propeller domain of various Plasmodium species.
Sequences of the kelch propeller domain are shown for P. falciparum, P. vivax, P. cynomolgi strain B, P. cynomolgi Gombok, P. knowlesi, P. inui, P. simiovale, P. simium, P. yoelii, and P. chabaudi. Nucleotides are highlighted based on disagreement with the reference P. falciparum K13 sequence. The yellow annotation below the P. falciparum sequence indicates the gene region that encodes the kelch propeller domain.
https://doi.org/10.1371/journal.pone.0136099.s001
(PDF)
S2 Fig. Amino acid sequence alignment of the kelch propeller domain of various Plasmodium species.
Translation of kelch propeller domain nucleotide sequences are shown for P. falciparum, P. reichenowi, P. vivax, P. cynomolgi strain B, P. cynomolgi Gombok, P. knowlesi, P. inui, P. simiovale, P. simium, P. yoelii, and P. chabaudi. Highlighted are amino acid bases that are in disagreement with the reference P. falciparum kelch propeller sequence. The yellow annotation below the P. falciparum sequence indicates the gene region that encodes the kelch propeller domain.
https://doi.org/10.1371/journal.pone.0136099.s002
(PDF)
S3 Fig. K13 gene amplification using a previously described protocol.
The original K13 gene amplification protocol was tested on multiple Plasmodium species, including human, rodent, and non-human primate malaria parasites from various geographical regions. Rows (A) and (B) show human malaria parasites tested; Row (C) shows non-human primate and rodent malaria parasites tested. Results are shown separately for the primary and secondary reactions. Blue text denotes samples that were amplified by the PCR protocol.
https://doi.org/10.1371/journal.pone.0136099.s003
(TIFF)
Acknowledgments
We acknowledge support from the Advanced Molecular Detection Initiative at the CDC. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Author Contributions
Conceived and designed the experiments: ET. Performed the experiments: ET IFG JAN DSP. Analyzed the data: ET. Contributed reagents/materials/analysis tools: JWB. Wrote the paper: ET. Helped edit the manuscript: VU SMC MMP JWB.
References
- 1.
WHO, Global report on antimalarial drug efficacy and drug resistance: 2000–2010. 2010: World Health Organization. Geneva.
- 2. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M., et al., Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med, 2008. 359(24): p. 2619–20. pmid:19064625
- 3. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., et al., Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med, 2009. 361(5): p. 455–67. pmid:19641202
- 4. Amaratunga C., Sreng S., Suon S., Phelps E.S., Stepniewska K., Lim P., et al., Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis, 2012. 12(11): p. 851–8. pmid:22940027
- 5. Phyo A.P., Nkhoma S., Stepniewska K., Ashley E.A., Nair S., McGready R., et al., Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet, 2012. 379(9830): p. 1960–6. pmid:22484134
- 6. Carrara V.I., Lwin K.M., Phyo A.P., Ashley E., Wiladphaingern J., Sriprawat K., et al., Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999–2011: an observational study. PLoS Med, 2013. 10(3): p. e1001398. pmid:23472056
- 7. Takala-Harrison S., Clark T.G., Jacob C.G., Cummings M.P., Miotto O., Dondorp A.M., et al., Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A, 2013. 110(1): p. 240–5. pmid:23248304
- 8. Ashley E.A., Dhorda M., Fairhurst R.M., Amaratunga C., Lim P., Suon S., et al., Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med, 2014. 371(5): p. 411–23. pmid:25075834
- 9. Takala-Harrison S., Jacob C.G., Arze C., Cummings M.P., Silva J.C., Dondorp A.M., et al., Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. J Infect Dis, 2014.
- 10. Talundzic E., Okoth S.A., Congpuong K., Plucinski M.M., Morton L., Goldman I.F., et al., Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog, 2015. 11(4): p. e1004789. pmid:25836766
- 11. Wellems T.E. and Plowe C.V., Chloroquine-resistant malaria. J Infect Dis, 2001. 184(6): p. 770–6. pmid:11517439
- 12. Wootton J.C., Feng X., Ferdig M.T., Cooper R.A., Mu J., Baruch D.I., et al., Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature, 2002. 418(6895): p. 320–3. pmid:12124623
- 13. Na-Bangchang K. and Congpuong K., Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J Exp Med, 2007. 211(2): p. 99–113. pmid:17287593
- 14. Ariey F., Witkowski B., Amaratunga C., Beghain J., Langlois A.C., Khim N., et al., A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature, 2014. 505(7481): p. 50–5. pmid:24352242
- 15. Bosman P., Stassijns J., Nackers F., Canier L., Kim N., Khim S., et al., Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study. Malar J, 2014. 13: p. 394. pmid:25288380
- 16. Kamau E., Campino S., Amenga-Etego L., Drury E., Ishengoma D., Johnson K., et al., K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis, 2014.
- 17. Mohon A.N., Alam M.S., Bayih A.G., Folefoc A., Shahinas D., Haque R., et al., Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). Malar J, 2014. 13(1): p. 431.
- 18. Plucinski M.M., Talundzic E., Morton L., Dimbu P.R., Macaia A.P., Fortes F., et al., Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Children in Zaire and Uige Provinces, Angola. Antimicrob Agents Chemother, 2014.
- 19. Taylor S.M., Parobek C.M., DeConti D.K., Kayentao K., Coulibaly S.O., Greenwood B.M., et al., Absence of Putative Artemisinin Resistance Mutations Among Plasmodium falciparum in Sub-Saharan Africa: A Molecular Epidemiologic Study. J Infect Dis, 2014.
- 20. Sattabongkot J., Tsuboi T., Zollner G.E., Sirichaisinthop J., and Cui L., Plasmodium vivax transmission: chances for control? Trends Parasitol, 2004. 20(4): p. 192–8. pmid:15099559
- 21. Popovici J., Kao S., Eal L., Bin S., Kim S., and Menard D., Reduced polymorphism in the Kelch propeller domain in Plasmodium vivax isolates from Cambodia. Antimicrob Agents Chemother, 2015. 59(1): p. 730–3. pmid:25385109
- 22. Douglas N.M., Anstey N.M., Angus B.J., Nosten F., and Price R.N., Artemisinin combination therapy for vivax malaria. Lancet Infect Dis, 2010. 10(6): p. 405–16. pmid:20510281
- 23. Gogtay N., Kannan S., Thatte U.M., Olliaro P.L., and Sinclair D., Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev, 2013. 10: p. CD008492. pmid:24163021
- 24. Khim N., Andrianaranjaka V., Popovici J., Kim S., Ratsimbasoa A., Benedet C., et al., Effects of mefloquine use on Plasmodium vivax multidrug resistance. Emerg Infect Dis, 2014. 20(10): p. 1637–44. pmid:25272023
- 25. Mangold K.A., Manson R.U., Koay E.S., Stephens L., Regner M., Thomson R.B. Jr., et al., Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol, 2005. 43(5): p. 2435–40. pmid:15872277
- 26. Lucchi N.W., Narayanan J., Karell M.A., Xayavong M., Kariuki S., DaSilva A.J., et al., Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. PLoS One, 2013. 8(2): p. e56677. pmid:23437209
- 27. Talundzic E., Maganga M., Masanja I.M., Peterson D.S., Udhayakumar V., and Lucchi N.W., Field evaluation of the photo-induced electron transfer fluorogenic primers (PET) real-time PCR for the detection of Plasmodium falciparum in Tanzania. Malar J, 2014. 13: p. 31. pmid:24467985
- 28. Yang Z., Lasker K., Schneidman-Duhovny D., Webb B., Huang C.C., Pettersen E.F., et al., UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol, 2012. 179(3): p. 269–78. pmid:21963794
- 29. Cui L., Yan G., Sattabongkot J., Cao Y., Chen B., Chen X., et al., Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop, 2012. 121(3): p. 227–39. pmid:21382335
- 30.
WHO, World Malaria Report 2014. 2014: The World Health Organization. Geneva.
- 31.
Collins, W.E., The primate malarias. 1971: ALERTAsia. 366.